highli
pathogen
avian
influenza
viru
hpaiv
long
carri
wild
aquat
bird
popul
spread
throughout
world
via
either
poultri
transport
migratori
bird
flyway
kill
led
cull
hundr
million
bird
shown
lethal
human
infect
human
case
hong
kong
die
although
virus
yet
transmit
human
crossspeci
transmiss
virus
human
document
case
mortal
rate
sinc
reemerg
virus
sever
recent
independ
studi
suggest
virus
might
requir
amino
acid
substitut
becom
transmiss
via
respiratori
droplet
mammal
therefor
great
concern
rais
abil
virus
effici
spread
human
becom
pandem
threat
thu
make
influenza
vaccin
integr
part
pandem
prepared
plan
broad
crossprotect
highli
desir
featur
vaccin
avoid
possibl
pandem
influenza
virus
howev
efficaci
current
licens
vaccin
appear
insuffici
partial
due
antigen
divers
present
viru
restrict
util
vaccin
small
number
specif
strain
whilst
ident
specif
pandem
strain
rather
difficult
predict
event
would
take
month
deliv
vaccin
use
current
manufactur
technolog
therefor
great
effort
made
toward
develop
vaccin
broad
crossprotect
influenza
virus
well
improv
vaccin
product
method
shorten
leadtim
vaccin
deliveri
new
approach
viruslik
particl
vlp
nake
dna
adenovir
vaccinia
vectorbas
vaccin
develop
prevent
viral
infect
report
inactiv
influenza
virus
clade
viruslik
particl
vlp
contain
ha
na
protein
show
signific
crossprotect
potenti
nonrepl
vaccinia
vector
modifi
vaccinia
viru
ankara
mva
carri
ha
deriv
strain
display
high
level
crossprotect
veterinari
vaccin
express
gene
abarhead
also
provid
protect
lethal
challeng
homolog
heterolog
avian
influenza
virus
previou
studi
gener
replic
modifi
vaccinia
tian
tan
mvtt
vaccinia
tian
tan
vtt
remov
hemagglutinin
gene
genom
region
hindiii
fragment
vtt
vtt
use
extens
smallpox
vaccin
million
peopl
china
success
develop
vaccin
vector
rabi
hepat
b
virus
compar
vtt
mvtt
safe
shown
replic
mous
brain
caus
death
intracrani
inject
bodi
weight
loss
intranas
inocul
immunodefici
mice
moreov
use
spike
glycoprotein
sarscov
test
antigen
found
mvtt
superior
mva
induc
high
level
neutral
antibodi
via
mucos
vaccin
report
use
mvtt
live
vaccin
vector
construct
mvtthaqh
mvtthaah
express
gene
goosederiv
qinghai
strain
abarhead
humanderiv
anhui
strain
determin
immunogen
efficaci
vaccin
construct
mice
homolog
heterolog
human
influenza
virus
haxjwsn
stand
recombin
influenza
viru
ha
gene
deriv
human
strain
seven
gene
revers
genet
system
kindli
provid
yoshiro
kawaoka
two
wildtyp
influenza
virus
use
challeng
studi
cultiv
embryon
spf
chicken
egg
beij
merial
vital
laboratori
anim
technolog
co
ltd
beij
china
ahaxjwsn
propag
madindarbi
canin
kidney
mdck
cell
mdck
cell
vero
cell
cultur
dulbecco
modifi
eagl
minimum
essenti
medium
dmem
supplement
fetal
calf
serum
fc
atmospher
allanto
fluid
cell
cultur
harvest
store
fifti
percent
mous
lethal
dose
strain
determin
femal
balbc
mice
fifti
percent
tissu
cultur
infecti
dose
titrat
mdck
cell
experi
conduct
biosafeti
laboratori
group
divers
pseudovirus
prepar
accord
recent
describ
method
ha
gene
amplifi
total
rna
viru
rtpcr
ha
gene
kindli
provid
dr
david
ho
amplifi
pcr
ha
orf
gene
insert
vaccinia
shuttl
vector
pzcxz
strong
synthet
promot
psyn
subsequ
recombin
promot
region
mvtt
ha
gene
gener
mvtthaqh
mvtthaah
use
homolog
recombin
method
transfect
previous
describ
brief
vero
cell
infect
mvtt
subsequ
transfect
shuttl
vector
pzcxz
contain
ha
gene
influenza
flank
mvtt
ha
sequenc
recombin
viru
select
six
round
plaqu
purif
agar
confirm
immunostain
assay
use
serum
insert
full
length
gene
ha
confirm
pcr
use
specif
primer
total
dna
extract
mvtthaqh
mvtthaah
mvttsiv
infect
vero
cell
describ
presenc
fulllength
ha
gene
evidenc
amplif
around
bp
fragment
use
follow
pair
primer
anhuif
anhuib
qinghaif
atggagaaaatagtgcttct
qinghaib
aatgcaaattctgcattgta
respect
mvtthaqh
mvtthaah
viral
stock
propag
vero
cell
purifi
ultracentrifug
sucros
cushion
viral
stock
titrat
simultan
vero
cell
plaqu
form
assay
use
crystal
violet
stain
count
plaqu
gfp
express
sixweekold
femal
balbc
mice
use
anim
experi
three
group
mice
group
immun
plaqu
format
unit
pfu
mvtthaqh
mvtthaah
intranas
intramuscular
oral
rout
day
day
respect
number
mice
includ
control
group
given
either
pb
mvtt
mvtt
recombin
viru
express
spike
glycoprotein
sarscov
recent
describ
blood
sampl
mous
collect
week
vaccin
measur
antibodi
respons
splenocyt
also
collect
measur
cellmedi
immun
respons
stimul
tcell
epitop
iystvassl
previous
describ
other
sera
mice
treat
receptordestroy
enzym
rde
purchas
institut
viral
diseas
control
prevent
chines
center
diseas
control
prevent
ratio
heatinactiv
minut
neutral
test
nt
use
divers
pseudovirus
perform
accord
recent
describ
method
haemagglutin
inhibit
hi
test
perform
chicken
red
blood
cell
accord
method
recommend
world
organ
anim
health
http
serum
sampl
also
test
neutral
antibodi
live
ahaxjwsn
tradit
microneutr
assay
briefli
heatinactiv
sera
first
twofold
dilut
dmem
mix
equal
volum
influenza
virus
incub
period
hour
serumviru
mixtur
transfer
onto
mdck
cell
plate
triplic
cell
observ
cytopath
effect
cpe
daili
consecut
day
titer
neutral
antibodi
defin
highest
serum
dilut
inhibit
format
cpe
cellmedi
immun
respons
determin
measur
releas
splenocyt
accord
previous
publish
elispot
assay
mous
model
commonli
use
evalu
vaccin
influenza
virus
isol
human
group
nine
mice
either
immun
pfu
mvtthaqh
mvtt
respect
twice
one
month
interv
immun
mice
challeng
either
week
post
second
immun
bodi
weight
chang
number
death
clinic
sign
close
monitor
viral
challeng
twice
day
anim
human
euthan
intraperiton
inject
pentobarbit
sodium
salt
mgkg
follow
cervic
disloc
weight
loss
greater
bodi
weight
start
experi
hour
pentobarbit
sodium
salt
use
minim
suffer
anim
percentag
surviv
calcul
previous
describ
measur
viral
replic
vivo
tissu
sampl
brain
lung
taken
two
mice
group
viral
isol
day
post
infect
respect
tissu
sampl
weigh
homogen
ml
supernat
inocul
allanto
caviti
dayold
embryon
spf
chicken
egg
allanto
fluid
subsequ
harvest
ha
activ
test
detect
viru
replic
anim
experi
evalu
immun
respons
repeat
least
twice
n
per
group
respons
mous
count
individu
data
point
statist
analysi
viru
challeng
studi
perform
twice
n
per
group
data
obtain
anim
studi
pseudotyp
viru
neutral
assay
examin
use
oneway
anova
differ
consid
signific
p
ha
gene
chosen
vaccin
construct
repres
prototyp
clade
highli
pathogen
influenza
virus
led
sporad
human
infect
around
world
fig
whilst
recommend
vaccin
strain
isol
human
patient
may
induc
better
immun
respons
human
isol
analyz
sequenc
ha
gene
deriv
human
strain
countri
compar
ha
major
antigen
site
within
clade
rel
conserv
despit
viral
evolut
occur
two
three
year
outsid
qinghai
lake
area
tabl
belong
clade
major
antigen
site
differ
clade
rather
conserv
within
clade
hypothes
vaccin
base
ha
would
least
offer
protect
human
influenza
virus
clade
modifi
shuttl
vector
pzcxz
construct
target
ha
gene
mvtt
genom
locat
mvtt
ha
gene
shuttl
vector
contain
dual
promot
allow
simultan
express
two
target
gene
within
vector
ha
gene
construct
strong
synthet
promot
psyn
wherea
report
gfp
rfp
gene
separ
rel
weaker
promot
ph
sinc
gene
includ
within
insert
frame
report
gene
serv
surrog
marker
select
recombin
vtt
carri
ha
gene
use
techniqu
abl
gener
purifi
recombin
viru
mvtthaqh
mvtthaah
posit
plaqu
select
fluoresc
microscop
subsequ
confirm
immunohistochemc
stain
assay
use
mous
serum
fig
confirm
full
length
gene
insert
mvtt
vector
total
dna
extract
vero
cell
infect
either
mvtthaqh
mvtthaah
total
dna
extract
mvttsiv
infect
vero
cell
neg
control
fulllength
ha
gene
amplifi
total
dna
extract
mvtthaqh
mvtthaah
infect
cell
use
specif
primer
mvttsiv
infect
vero
cell
fig
result
confirm
success
construct
mvtt
viru
express
gene
strain
respect
determin
immunogen
mvtthaqh
mvtthaah
two
group
mice
immun
twice
pfu
recombin
viru
day
day
via
intranas
intramuscular
im
rout
respect
serum
sampl
collect
day
day
first
immun
week
second
inocul
day
subject
neutral
nt
assay
use
previous
describ
pseudovir
assay
found
mvtthaqh
abl
induc
potent
nt
respons
autolog
viral
strain
dilut
factor
first
immun
fig
rout
induc
seemingli
higher
level
nt
respons
im
rout
first
immun
titer
vs
moreov
second
immun
boost
primari
respons
im
fold
nt
titer
mice
receiv
control
mvttsiv
gener
respons
expect
fig
contrast
immun
none
mice
immun
mvtthaah
abl
induc
nt
respons
homolog
strain
fig
therefor
conduct
immun
dose
mvtthaah
three
week
immun
one
five
mice
abl
produc
nt
respons
homolog
strain
titer
howev
mvtthaah
abl
induc
potent
nt
respons
dilut
factor
around
immun
qinghai
strain
fig
furthermor
compar
mvtthaqh
mvtthaah
induc
seemingli
lower
level
nt
respons
rout
im
rout
immun
immun
boost
primari
respons
nt
titer
result
suggest
immun
mvtthaah
success
howev
like
less
sensit
neutral
activ
vaccineinduc
antibodi
moreov
ha
less
antigen
compar
ha
qinghai
strain
chose
mvtthaqh
evalu
cell
mediat
respons
found
rout
vaccin
abl
induc
releas
tcell
measur
spot
form
count
sfc
use
elispot
assay
fig
averag
sfc
im
sfc
detect
among
one
million
splenocyt
thu
mvtthaqh
found
immunogen
mice
induc
antibodi
cellular
immun
respons
better
vaccin
candid
prevent
pandem
compar
mvtthaah
therefor
chose
mvtthaqh
evalu
determin
crossclad
nt
activ
mvtthaqh
test
immun
sera
group
diverg
influenza
pseudovirus
group
includ
virus
clade
qinghai
turkey
chines
duck
fujian
anhui
fig
tabl
although
level
crossneutr
vari
nab
induc
mvtthaqh
abl
neutral
pseudovirus
major
clade
test
fig
virus
clade
optim
inhibit
follow
clade
consist
amount
sequenc
variat
antigen
site
tabl
determin
efficaci
vaccin
three
group
mice
immun
twice
pfu
mvtthaqh
day
via
intranas
intramuscular
oral
administr
rout
respect
includ
oral
rout
one
easiest
method
vaccin
resourcelimit
set
serum
sampl
collect
day
vaccin
day
first
immun
week
second
inocul
day
subject
hi
nt
assay
use
live
homolog
strain
found
three
vaccin
rout
abl
induc
hi
nt
respons
tabl
rout
induc
seemingli
higher
level
hi
nt
respons
two
rout
first
immun
moreov
second
immun
boost
primari
respons
significantli
specif
fold
hi
fold
nt
titer
consist
find
use
pseudovir
neutral
assay
fig
unexpectedli
two
five
mice
oral
group
respond
vaccin
two
immun
unknown
reason
control
mice
receiv
pb
gener
respons
expect
conduct
elispot
assay
experi
anim
kept
subsequ
viral
challeng
determin
whether
vaccin
would
offer
protect
vaccin
anim
challeng
homolog
pathogen
viru
strain
three
week
second
immun
evalu
bodi
weight
chang
surviv
rate
found
anim
detect
antibodi
respons
complet
protect
fig
moreov
protect
mice
exhibit
clinic
sign
infect
includ
huddl
shiver
ruffl
fur
contrast
anim
receiv
pb
two
mice
show
detect
antibodi
respons
oral
group
show
signific
clinic
sign
infect
die
within
day
post
viral
challeng
determin
whether
mvtthaqh
would
confer
protect
heterolog
human
influenza
virus
immun
anoth
four
group
mice
via
im
rout
includ
mock
vaccin
mvtt
determin
whether
vaccin
vector
would
induc
nonspecif
protect
effect
use
vaccin
protocol
reduc
dosag
pfu
mvtthaqh
mvtthaqh
abl
induc
hi
nt
respons
expect
tabl
addit
homolog
viru
two
heterolog
human
virus
ahaxjwsn
includ
test
consist
antigen
analysi
tabl
similar
level
hi
nt
respons
detect
ahaxjwsn
compar
homolog
viru
tabl
despit
antigen
variat
hi
nt
respons
also
detect
clade
fig
tabl
expect
hi
nt
respons
detect
among
mice
immun
mvtt
determin
efficaci
mvtthaqh
vaccin
anim
challeng
pathogen
virus
week
post
second
immun
sinc
ahaxjwsn
pathogen
viru
includ
challeng
experi
consist
previou
find
fig
anim
detect
antibodi
respons
complet
protect
homolog
challeng
fig
protect
mice
exhibit
clinic
sign
infect
importantli
anim
detect
antibodi
respons
also
complet
protect
heterolog
challeng
fig
contrast
anim
receiv
mvtt
show
signific
clinic
sign
includ
huddl
shiver
ruffl
fur
bodi
weight
loss
die
within
day
post
viral
challeng
despit
occurr
clinic
sign
three
control
anim
one
im
group
two
group
surviv
challeng
unknown
reason
fig
determin
whether
mvtthaqhinduc
immun
respons
could
prevent
viral
replic
vivo
two
mice
group
sacrif
day
post
challeng
respect
sampl
lung
brain
subject
viral
isol
agreement
data
shown
fig
virus
obtain
mice
vaccin
mvtthaqh
tabl
contrast
virus
readili
isol
mice
receiv
mvtt
interestingli
day
post
viral
challeng
easili
detect
wherea
suggest
higher
infect
like
higher
pathogen
former
viru
murin
model
studi
investig
breath
efficaci
two
mvtt
base
vaccin
express
deriv
abarhead
homolog
heterolog
human
influenza
virus
hpaiv
consid
seriou
public
health
threat
pandem
potenti
hpaiv
pandem
occur
estim
claim
live
hundr
million
peopl
howev
current
licens
vaccin
effect
small
number
specif
strain
difficulti
predict
pandem
strain
togeth
long
slow
process
vaccin
product
make
effici
develop
vaccin
broad
crossprotect
import
step
pandem
prepared
describ
modifi
vaccinia
viru
tiantan
strain
mvtt
base
vaccin
express
gene
goosederiv
qinghai
strain
abarhead
induc
broadli
neutral
antibodi
crossclad
protect
immun
mice
current
human
vaccin
mainli
focus
clade
strain
among
vaccin
extens
studi
contrast
although
recommend
world
health
organ
one
vaccin
target
strain
yet
comprehens
studi
potenti
human
vaccin
candid
past
year
virus
close
relat
found
spread
rapidli
europ
india
africa
via
migratori
bird
like
caus
agent
sever
human
infect
throughout
europ
china
includ
recent
identifi
studi
character
immunogen
mvtthaqh
mvtthaah
antibodi
respons
induc
multipl
influenza
virus
repres
clade
qinghai
turkey
chines
duck
fujian
anhui
fig
use
pseudovir
nt
assay
found
nab
induc
mvtthaqh
neutral
pseudovirus
major
clade
test
mvtthaqhinduc
serum
inhibit
virus
clade
optim
follow
clade
suggest
sequenc
variat
antigen
site
probabl
account
reduc
nt
titer
diverg
strain
tabl
moreov
character
mvtthaqh
induc
antibodi
respons
human
strain
fig
viru
recent
identifi
chines
patient
xinjiang
provinc
northwest
qinghai
provinc
despit
sequenc
variat
antigen
site
probabl
due
adapt
infect
human
tabl
ha
gene
remain
close
relat
fig
therefor
surpris
see
mvtthaqh
induc
neutral
hi
antibodi
respons
react
equal
well
haxjwsn
tabl
particular
mutat
seem
confer
resist
nt
hi
antibodi
induc
mvtthaqh
tabl
furthermor
determin
crossreact
nt
hi
antibodi
anoth
human
viru
clade
interestingli
although
ten
major
antigen
mutat
identifi
tabl
account
titer
drop
hi
live
viral
nt
assay
tabl
mvtthaqh
still
abl
induc
signific
level
nt
hi
antibodi
respons
heterolog
human
strain
importantli
mvtthaqhvaccin
complet
protect
challeng
pathogen
respect
fig
find
indic
mvtthaqh
display
potenti
overcom
problem
antigen
drift
clade
clade
therefor
attract
target
vaccin
clinic
develop
appear
weak
antigen
use
mvtt
vector
like
caus
mutat
induc
conform
chang
hid
antigen
site
ha
tabl
ha
protein
effici
express
mvtthaah
infect
vero
cell
fig
mvtthaah
abl
induc
nt
respons
immun
qinghai
strain
fig
consist
less
sensit
neutral
activ
mvtthaqhinduc
antibodi
compar
influenza
virus
includ
strain
also
belong
clade
fig
two
five
mice
oral
administr
group
respond
mvtthaqh
vaccin
two
immun
due
individu
varianc
mvttbase
vaccin
offer
certain
advantag
convent
influenza
vaccin
recent
technic
improv
time
requir
construct
mvttbase
vaccin
becom
significantli
shorten
comparison
adenovector
dnabas
vaccin
vaccinia
deliv
high
level
foreign
gene
express
directli
without
timeconsum
geneoptim
procedur
critic
mvtthaqh
depend
spf
egg
primari
chicken
embryo
fibroblast
mvtthaqh
produc
use
whorecommend
vero
cell
eas
without
requir
biosafeti
contain
necessari
inactiv
vaccin
largescal
product
mvtthaqh
therefor
feasibl
given
larg
capac
hous
larg
foreign
gene
insert
possibl
use
mvtt
gener
vaccin
order
improv
breath
crossclad
nt
hi
antibodi
respons
compar
widelyus
modifi
vaccinia
ankara
mva
vector
recent
demonstr
mvtt
superior
mva
induc
high
level
system
neutral
antibodi
sar
coronaviru
especi
mucos
rout
vaccin
end
found
intranas
vaccin
mvtthaqh
induc
consist
high
level
system
nt
hi
antibodi
respons
equival
outcom
intramuscular
inject
moreov
intranas
vaccin
overcom
preexist
antivector
immun
respons
offer
advantag
elderli
previous
receiv
vtt
smallpox
noninvas
procedur
intranas
vaccin
also
great
implic
mass
vaccin
human
popul
especi
develop
countri
lastli
intranas
vaccin
made
possibl
develop
mvtthaqh
potenti
aerosol
veterinari
vaccin
howev
would
requir
efficaci
test
spray
onto
poultri
migratori
bird
popul
given
reason
find
studi
import
implic
fight
possibl
zoonot
hpaiv
outbreak
